An overview of the latest news in Parkinson disease reported across MJH Life Sciences™.
An overview of the latest news in Parkinson disease (PD) reported across MJH Life Sciences™.
Amantadine Found to Improve Motor Function, Dyskinesia in PD
According to results from 2 randomized phase 3 trials, amantadine extended-release capsules, sold as Gocovri, were associated with significant improvements in dyskinesia and motor aspects of experiences of living (M-EDLs) in people with PD.
As reported by NeurologyLive®, participants with PD who had been taking levodopa for 7.7 years and experiencing dyskinesia for 3.8 years were randomized to receive either amantadine or placebo across a 12-week period. Analyzed via the Movement Disorder Society Unified Parkinson’s Disease Rating Scale, changes from baseline to week 12 showed a treatment difference of –2.0 (P = .004) for amantadine vs placebo, with the intervention group’s change from baseline exceeding a published minimal clinically important difference threshold of 3.05 points.
Moreover, participants of the intervention group showcased significant improvements in several M-EDLs, including freezing of gait; tremor; getting up from bed, chairs, and deep seats; and eating tasks. Amantadine is currently the only approved therapy in the United States to treat both OFF episodes and dyskinesia in patients with PD.
Progression of Advanced PD May Affect Treatment
In a Peer Exchange series by NeurologyLive®, titled, “Recognizing and Managing Advanced Parkinson Disease,” panelists discussed the natural progression of PD from initial diagnosis to advanced disease.
Highlighting the heterogeneity of the condition, there are several signs of advanced PD, particularly waning efficacy of treatments. Along with other signs of disease progression, such as newfound tremors or mood changes, panelists noted that as PD advances, symptoms become more difficult to treat with medications.
Speaking on the optimal time to start medications or integrate novel management strategies, including speech therapy and exercise, they said that when symptoms are disabling and have a clear impact on a patient’s functionality and quality of life, interventions should be implemented.
Spotlighting Prescription of Dementia-Linked Medications
Based on study findings published in Journal of the American Geriatrics Society, alerts sent via electronic health records (EHRs) to reduce the prescribing of high-risk medications associated with dementia in older adults were more than likely to remain unread in primary care sites.
Focusing on anticholinergics, which affect the brain by blocking a nervous system neurotransmitter that influences memory and alertness, called acetylcholine, the study authors noted these drugs have been linked with dementia. However, they are prescribed for many conditions in older adults, including PD, which may increase risk of dementia in an already at-risk patient population.
Notably, 85% of EHR alerts to providers and 95% of alerts to medical assistants about the risk posed by anticholinergic medications went unread. In improving education and methods of communication with primary care providers, human-based strategies or a policy-based component were cited to reduce use of high-risk medications.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More